Cannabidiol prescription in clinical practice: an audit on the first 400 patients in New Zealand.
analgesics
anti-anxiety agents
cannabidiol
cannabis
chronic pain
community care
depression
mental health
patient reported outcome measures
prescribing
therapy in mental health
Journal
BJGP open
ISSN: 2398-3795
Titre abrégé: BJGP Open
Pays: England
ID NLM: 101713531
Informations de publication
Date de publication:
2020
2020
Historique:
received:
12
08
2019
accepted:
24
09
2019
pubmed:
6
2
2020
medline:
6
2
2020
entrez:
6
2
2020
Statut:
epublish
Résumé
Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear. To review the changes in self-reported quality of life measurements, drug tolerability, and dose-dependent relationships in patients prescribed CBD oil for various conditions at a single institution. An audit including all patients ( Four hundred patients were assessed for CBD and 397 received a prescription. Follow-up was completed on 253 patients (63.3%). Patients reported a mean increase of 13.6 points ( There may be analgesic and anxiolytic benefits of CBD in patients with non-cancer chronic pain and mental health conditions such as anxiety. CBD is well tolerated, making it safe to trial for non-cancer chronic pain, mental health, neurological, and cancer symptoms.
Sections du résumé
BACKGROUND
BACKGROUND
Cannabidiol (CBD) is the non-euphoriant component of cannabis. In 2017, the New Zealand Misuse of Drugs Regulations (1977) were amended, allowing doctors to prescribe CBD. Therapeutic benefit and tolerability of CBD remains unclear.
AIM
OBJECTIVE
To review the changes in self-reported quality of life measurements, drug tolerability, and dose-dependent relationships in patients prescribed CBD oil for various conditions at a single institution.
DESIGN & SETTING
METHODS
An audit including all patients (
RESULTS
RESULTS
Four hundred patients were assessed for CBD and 397 received a prescription. Follow-up was completed on 253 patients (63.3%). Patients reported a mean increase of 13.6 points (
CONCLUSION
CONCLUSIONS
There may be analgesic and anxiolytic benefits of CBD in patients with non-cancer chronic pain and mental health conditions such as anxiety. CBD is well tolerated, making it safe to trial for non-cancer chronic pain, mental health, neurological, and cancer symptoms.
Identifiants
pubmed: 32019776
pii: bjgpopen20X101010
doi: 10.3399/bjgpopen20X101010
pmc: PMC7330185
pii:
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
Copyright © 2020, The Authors.
Références
J Exp Med. 2012 Jun 4;209(6):1121-34
pubmed: 22585736
Neuropsychopharmacology. 2011 May;36(6):1219-26
pubmed: 21307846
Pharmacol Res. 2017 Jul;121:213-218
pubmed: 28501518
Cannabis Cannabinoid Res. 2017 Jun 01;2(1):139-154
pubmed: 28861514
Perm J. 2019;23:18-041
pubmed: 30624194
CNS Drugs. 2018 Nov;32(11):1053-1067
pubmed: 30374683
N Engl J Med. 2018 May 17;378(20):1888-1897
pubmed: 29768152
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Neurology. 2015 Feb 24;84(8):794-802
pubmed: 25632091
Br J Pharmacol. 2011 Feb;162(3):584-96
pubmed: 20942863
J Pharmacol Exp Ther. 2006 Feb;316(2):780-8
pubmed: 16258021
Transl Psychiatry. 2012 Mar 20;2:e94
pubmed: 22832859
Brain Res. 2012 Jan 11;1431:46-52
pubmed: 22133305
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Braz J Psychiatry. 2008 Sep;30(3):271-80
pubmed: 18833429
J Psychopharmacol. 1993 Jan;7(1 Suppl):82-8
pubmed: 22290374
Pain. 2019 Jan;160(1):136-150
pubmed: 30157131
N Engl J Med. 2017 May 25;376(21):2011-2020
pubmed: 28538134
Cochrane Database Syst Rev. 2013 Apr 30;(4):CD005175
pubmed: 23633327
J Psychopharmacol. 2011 Jan;25(1):121-30
pubmed: 20829306
Can Fam Physician. 2018 Feb;64(2):111-120
pubmed: 29449241
Front Pharmacol. 2017 May 11;8:259
pubmed: 28553229